Outcome of Board Meeting

TITAN BIOTECH LIMITED Office: 903-909. 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387 November 05, 2026 Corporate Services Department, BSE Ltd., Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai- 400001 BSE Scrip Code: 524717 ISIN: INE150C01029 Dear Sir, Sub: Outcome of Meeting of the Board of Directors of Titan Biotech Limited (the Company) held on November 05, 2026 In terms of the requirements of Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circulars, as amended from time to time, this is to inform you that the Board of Directors at its meeting held today, i.e. Thursday, November 05, 2026, has, inter- alia approved the Unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30, 2026 as reviewed by the Audit Committee and approved by the Board of Directors of the Company. Please find enclosed, unaudited financial result (Standalone & Consolidated) along with the Limited Review Report issued by the statutory auditors of the Company for the quarter and half year ended September 30, 2026. The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:32 P.M. The above information will be available on the website of the company i.e www.titanbiotechltd.com and BSE Ltd i.e www.bseindia.com. Request to kindly take this information on record and acknowledge. For and on behalf of Titan Biotech Limited Charanjit Singh Company Secretary & Compliance Officer M.No A12726 Encl: As above Regd Office & Work: Unit I: A-902 A, RIICO. Industrial Area, Phase-III, Bhiwadi 301019, Rajasthan Unit II - E 539-540 RIICO. Industrial Area, Chopanki, Bhiwadi 301019, Rajasthan Unit III - F 689-690 RIICO. Industrial Area, Chopanki, Bhiwadi 301019, Rajasthan Email: cs@titanbiotechltd.com I Website: www.titanbiotechltd.com Independent Auditor’s Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) THE BOARD OF DIRECTORS TITAN BIOTECH LIMITED 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended September 30, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For A N S K & Associates Chartered Accountants Firm’s Registration No. 026177N (CA Kapil Singal) Partner M.No. 520205 Date: November 05, 2026 Place: New Delhi UDIN: 26520205VGMPVV3634 TITAN BIOTECH LIMITED Regd. Office - A-902 A, RICO Industrial Area, Phase 111, Bhiwadi, Rajasthan-301019 Phone No. 011- 71239900, Email : hrd@titanblotechitd.com, www.titanblotechitd.com, CIN : L74999R11992PLC013387 STATENENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTIS ENDED ON 30TH SEPTEMBER, 2026 (Rs. IN LAKHS) except for EPS T STANDALONE. ™ ‘QUARTER ENDED SIX MONTHS ENDED VEAR ENDED s LA L AIL 30.09.2026 30.06.2026 30093025 | 30092026 | 3009.2025 31032026 . UNAUDITED | UNAUDITED | UNAUDITED | UNAUDITED | UNAUDITED | AUDITED 1 NcomE Resenue fiom operations 764625 591666 sa3547 1356201 1008511 2061963 (Other wcome 17203 18126 13245 35329 20467 9102 Totalincome 781828 6,097.92 556191 1391620 10,289.78 21,160.05| 7 NSES Costof materals consumed 395109 299280 270273 691389 459801 991635 |Changes m mventones of fimshed goods. stock-in-traadned work-in-progscss a2 20391) (13786) (16279) 40181 (2982 |Employee benefits expense 96670 869 68 73826 1836 38 1439 58 323620 [Finance cous 2797 1988 241 4785 4193 9139 Depreciion and amorizaion expense 132,50 13669 12095 26919 23615 9253 {0ther expenses 118630 1,009.36 115957 219566 183923 390293 ot expenses 630568 482450 4,636.06 11,130.18 855671 17.342.60 * Profit before exceptional items and tax (1-2) 151260 1.23 42 92186 278602 1.733.07 381745 4 [Eeponal wems . 3 s - *__|Profit before tay (34) 151260 127342 92186 2,786 02 1,73307 381745 o [1ay expense 1) Cument iy 37976 32179 23155 70155 238 98374 {ID Defened tax (025)] 604 406 579 691 8399 i Farheycrur taves 002 B E 002 : - ) ENTRIE) 37953 278 23561 70736 3078 107273 rofit for the period (56) 1.133.07 94559 68625 207866 130233 274472 5[ Oher comprehensive income |1 uems that wil nt be reclassiied o profitorfoss + () Re-measurement gain on defined bencfit plans (G.04) (305) 244 (6.09)] 488 (1219 |01 Income tax on the above tem 076 077 062) 1S3 (123) 354 100 tems that wal be reclasssified 10 profit or loss G = - _|in) Incoamx oen the above item - 5 = otal other comprehensive income for the period (A+B) (net of taxes) (228) (2.28) 182 (4.56) 3.65 (8.65) 9| Total comprehensive income for the period (7+3) 1,130.79] 94331 683.07) 2,074.10) 1,305.98] 273607} 10 |Pasd-up cquny share capital (face value of Rs. 2/- each) 82637] 826 37) 826 37] 82637 826 37| 826 37} 11 [Ooher Equiy 1625778} 12 [Lamiags per equiry share (face value of Rs 2/- each) not annualised (1) Basic 274 229 830 503 15.76. 664 21 Ditued 274 229 330 503 1576 66¢ Notes: I The above unaudited siandalone financial esults for the quarter and six months ended on 30 09.2026 have been reviewed by the Audit Cominicaned taken on record by the Board of Directors of the Company at its meeting held on November 05, 2026 The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure: Requinments). 2015 The resalts for the quaner and six months ended on 30th Sept. 2020, are available on the BSE Limited website(www bscindia com) and on the company’s Website(www fitmbiotechid com) Picvious peniod figures are regr [Showing first 8,000 characters — download PDF for full document]